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Abstract
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Primary tumors are often heterogeneous, composed of therapy-sensitive and emerging therapyresistant cancer cells. Interestingly, treatment of therapy-sensitive tumors in heterogeneous tumor
microenvironments results in apoptosis of therapy-resistant tumors. In this study, we identify a
Par-4 amino-terminal fragment (PAF) that is released by diverse therapy-sensitive cancer cells
following therapy-induced caspase cleavage of the tumor suppressor Par-4 protein. PAF caused
apoptosis in cancer cells resistant to therapy and inhibited tumor growth. A VASA segment of
Par-4 mediated its binding and degradation by the ubiquitin ligase Fbxo45, resulting in loss of
Par-4 pro-apoptotic function. Conversely, PAF, which contains this VASA segment, competitively
bound to Fbxo45 and rescued Par-4-mediated induction of cancer cell-specific apoptosis.
Collectively, our findings identify a molecular decoy naturally generated during apoptosis that
inhibits a ubiquitin ligase to overcome therapy resistance in tumors.
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Introduction
Most tumors are phenotypically and functionally heterogeneous owing to their multi-clonal
nature, genetic instability and tumor cell plasticity (1,2). Primary tumors are usually
responsive to the standard-of-care therapy aimed largely at reducing tumor bulk, and
therapy-resistant tumor cells emerge mainly at distant metastatic sites, and less frequently at
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the primary site, within a few years after the primary tumor has regressed (3). These
observations indicate that a dynamic relationship exists between the treatment of primary
tumors and emergence of resistant clones. To understand the mechanisms of tumor
resistance to therapy, we are studying the relationship between therapy-sensitive and
therapy-resistant tumor cells. Our studies indicated that therapy-resistant cancer cells
undergo apoptosis if the therapy-sensitive cancer cells in a heterogeneous tumor
microenvironment are induced to undergo apoptosis. This paracrine effect of the therapysensitive tumor cells undergoing apoptosis was attributed to a therapy-induced, caspasecleavage fragment of the tumor suppressor prostate apoptosis response-4 (Par-4) protein.

Author Manuscript

Par-4 is a leucine zipper domain containing protein that is ubiquitously expressed in diverse
cell types and tissues (4,5). Par-4 induces apoptosis specifically in cancer cells but not in
normal cells by intracellular and extracellular mechanisms (6). Par-4-knockout mice develop
spontaneous, as well as inducible tumors (7), and corollarily, transgenic mice overexpressing
Par-4 are resistant to the growth of spontaneous or oncogene-inducible tumors (8).
Consistent with its tumor suppressor function, a number of laboratories have reported that
Par-4 is inactivated, down-regulated, or mutated in different types of cancers (9–11).
Par-4 protein is secreted in response to various endoplasmic stress-producing agents or small
molecule secretagogues and induces apoptosis specifically in cancer cells leading to growth
inhibition of tumors (12–14). Secreted Par-4 binds, via its SAC domain, to its receptor
GRP78 on the surface of cancer cells and induces apoptosis by a FADD/caspase 8/caspase 3
dependent pathway (15). Normal cells, on the other hand, are resistant to apoptosis by
extracellular Par-4 as they express low to undetectable levels of basal or inducible cell
surface GRP78 receptors (15).

Author Manuscript

Several reports have indicated that cells undergoing apoptosis can release factors that induce
paracrine apoptosis of neighboring cells in the microenvironment; however, the precise
factor(s) has been elusive (16). We tested the hypothesis that treatment of therapy-sensitive
cancer cells with apoptosis-inducing therapeutics may induce paracrine apoptosis in
neighboring therapy-resistant cancer cells grown in heterogeneous microenvironments.
Rather unexpectedly, we identified an amino-terminal fragment of Par-4 that is naturally
produced and released from therapy-sensitive cancer cells following caspase-dependent
cleavage of Par-4. This Par-4 fragment specifically enters cancer cells, including those that
are resistant to therapy, and induces apoptosis.

Materials and Methods
Author Manuscript

Cells
Human prostate cancer cells DU145, PC-3, LNCaP, lung cancer cells A549 and H460, breast
cancer cells MCF7, and primary human lung fibroblast cells HEL were from ATCC, MD.
Human colon cancer cells KM20 were from Mark Evers (University of Kentucky). Parent
A549 and A549TR cells were from Bruce Zetter (Boston Children’s Hospital, MA) (17).
Mel1617 and Mel1617BR melanoma cells were from Meenhard Herlyn (Wistar Institute,
PA)(18). Beas2B and arsenic-transformed Beas2B cells were from Xianglin Shi (University
of Kentucky). C4-2B cells were from Leland Chung (Ceder Sinai Medical Center, LA).
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Normal human prostate stromal cells PrS and prostate epithelial cells PrE were from Lonza
Inc. (Allendale, NJ). KP7B cells were from Tyler Jacks (MIT, MA). PC-3/dnFADD or PC-3/
FLIP cells were previously described (15). Par-4+/+ and Par-4−/− MEFs were from wild type
and Par-4-null C57BL/6 mouse embryos. All the cell lines were obtained between 2011 and
2012 and authenticated by us in August 2012, and again in December 2016, via STR
profiling by Genetica DNA Laboratories (Burlington, NC). Mycoplasma contamination in
the cell cultures was ruled out by using the MycoAlert™ Mycoplasma Detection Kit (from
Lonza). The length of time between thawing and use of the cell lines in the described
experiments was two to four weeks.
Recombinant Proteins

Author Manuscript

Purified recombinant thioredoxin (TRX), TRX-Par-4 and TRX-PAF were procured from
ProMab Biotechnologies Inc, as described previously (15). Purified His-PAF or His-TRX
was prepared using the baculoviral protein expression system (GenScript, NJ).
Reagents
Paclitaxel injection vials were obtained from the Markey Cancer Center pharmacy for
research use only. Caspase inhibitors z-VAD-fmk, z-DEVD, z-IETD-fmk, z-LEHD-fmk
were from BioVision Inc. Recombinant human TRAIL was from Calbiochem. BFA was
procured from Sigma. PLX4720 was from Plexxikon Inc., CA.
Plasmid Constructs

Author Manuscript

Plasmids for expression of vector pCB6+, pCB6+/GFP, non GFP tagged pCB6+/Par-4,
Par-4-GFP, and pcDNA3.1-nV5 Par-4/3A mutant have been described previously (8, 19).
The expression constructs for PAF, PAF/3A mutant and deletion mutants (132-340aa; or
30-131aa, 60-131aa, and 90-131aa tagged with GFP at the C-terminus) were cloned into the
pCB6+ vector backbone following PCR amplification of the cDNA using pCB6+/Par-4 or
pcDNA3.1-nV5 Par-4-3A constructs, respectively, as templates. The pCB6+ vector was
digested using the restriction enzyme EcoR1, and the cDNA was then ligated into the vector.
Fidelity of the sequence was confirmed by nucleotide sequencing. The shRNA for Par-4 was
constructed using the pLKO.1 vector and stable cell lines were generated by Sunil Nooti in
our laboratory. The 16aa fragment containing wild type VASA domain (ELNNNL) or VASA
mutant (ALANAL) was synthesized by GenScript, NJ.
Antibodies

Author Manuscript

Antibodies for Par-4 N-terminal (R334); GRP78 (N20), and Col1A1 (H-197), were from
Santa Cruz Biotechnology, Inc. Par-4 C-terminal antibody (P5367) was from Sigma-Aldrich,
USA. Fbxo45 antibody (ab136614) was from Abcam or was custom prepared as previously
described (19). Active caspase 3 antibody (Asp175) (5A1E) was from Cell Signaling. The βactin antibody was from Sigma-Aldrich.
Co-immunoprecipitation and Western blot analysis
Cells were lysed using RIPA (Radio Immuno Precipitation Assay) buffer and Complete
Protease Inhibitor cocktail (Roche) on ice. The lysates were centrifuged at 13000 rpm for 5
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minutes at 4°C and the supernatant was used for the pull-down. The protein concentration
was determined by Bradford assay using a cuvette based spectrophotometer. The proteins
were immunoprecipitated using 1 mg of input and 2 μg antibody and 25 μl bed volume of
magnetic protein A/G beads from ThermoFisher Scientific. The proteins were then eluted
and resolved using SDS-PAGE. The Western blot analysis was carried out as described
previously (10).
Apoptosis and Cell Proliferation Assays

Author Manuscript

Cancer cell killing by PAF was measured in blinded experiments using CellTiter 96®
AQueous MTS Reagent (Promega). The cells were seeded in 96- well plates and after 72 h
of treatment, the MTS assay was performed as per the manufacturer’s instructions. The
absorbance was measured at 490nm using a microplate reader (Spectra MR, DYNEX
Technologies). Apoptotic cells were identified by immunocytochemical (ICC) analysis for
active caspase-3, and apoptotic nuclei were revealed by 4, 6-diamidino-2-phenylindole
(DAPI) staining as previously described (12). A total of three independent and blinded
experiments were performed; and approximately 500 cells were scored in each experiment
for apoptosis under a fluorescent microscope. Data shown represent mean of three
independent experiments ± Standard Deviation (SD).
Animal experiments

Author Manuscript

Male athymic mice (nu/nu; from Jackson Laboratories at 6 weeks of age) were injected s.c.
with 1.5×106 cells of either A549 or A549TR/GFP cells into both the flanks. In the group
with mixed tumors, 1.5×106 cells of each cell type (A549 and A549TR/GFP) were mixed
and injected into the flanks. Following tumor formation, the animals were treated with
Paclitaxel (12 mg/kg) or injectable saline as vehicle control. The animal procedures were
performed blinded. The tumors were measured using Vernier calipers every 3 days for
period of 24 days. The tumors were excised and subjected to GFP immunohistochemical
analysis or TUNEL staining to evaluate apoptosis.
Lewis Lung Carcinoma (LLC1) cells (from ATCC, MD; 0.4 × 106 cells) were injected into
the athymic (nu/nu) mice through the tail vein, and 5 h later, the animals received 250 μg of
protein via the i.v. route. The animal procedures were performed as blinded experiments.
The tumors were allowed to develop for a period of 18 days, and then the animals were
humanely killed and the lungs were stained with India ink. The tumors nodules were
counted with the aid of a dissection microscope. All animal procedures were performed with
University of Kentucky IACUC approval.

Author Manuscript

Statistical analysis
All in vivo and cell death experiments were blinded, and the cell death experiments were
performed independently at least three different times, to verify the reproducibility of the
findings. A mean of at least 3 experiments ± Standard Deviation (S.D.) was calculated.
Statistical analyses were carried out with Graphpad Prism or Microsoft Excel software, and
P values were calculated using the Student t test.
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Results
Tumor cell heterogeneity permits cancer therapeutics to overcome therapy resistance

Author Manuscript

Paclitaxel, representing the taxane family of drugs, is commonly used as a standard of care
therapy for a broad range of cancers (20,21). To test the effect of Paclitaxel on taxaneresistant cancer cells grown within the microenvironment of taxane-sensitive cancer cells,
we treated co-cultures of RFP-tagged Paclitaxel-sensitive lung cancer cells A549 and GFPtagged Paclitaxel-resistant A549TR cells with Paclitaxel. Treatment of the co-cultures with
Paclitaxel resulted in apoptosis of the A549/RFP cells, as well as A549TR/GFP cells (Figure
1A). On the other hand, when grown separately, A549/RFP cells were susceptible to
Paclitaxel induced apoptosis but the A549TR/GFP cells were resistant to Paclitaxel (Figure
1A). The conditioned medium (CM) from Paclitaxel-treated A549/RFP cells induced
apoptosis in A549TR/GFP (Supplementary Figure S1A), implying that apoptosis was
induced by a factor released by A549/RFP cells.

Author Manuscript

To determine the in vivo significance of these observations in a heterogeneous tumor
microenvironment, we injected a mixture of A549 and A549TR/GFP cells into the flanks of
nude mice. As control, mice were injected with either A549 cells or A549TR/GFP cells.
Interestingly, Paclitaxel treatment caused remarkable inhibition of mixed tumor-cell
xenografts containing A549 and A549TR/GFP cells (Figure 1B). By contrast, xenografts of
A549TR/GFP cells injected separately in the flanks of mice were resistant to Paclitaxel
(Figure 1B). As expected, A549-derived xenografts were sensitive to Paclitaxel (Figure 1B).
TUNEL assays confirmed significant apoptosis with Paclitaxel in the A549TR/GFP cells
within the tumors arising from co-injection of A549 and A549TR/GFP cells (Figure 1B).
Together, these findings indicate paracrine apoptosis in Paclitaxel-resistant lung cancer cells
and tumor shrinkage produced by a soluble factor, which was released by Paclitaxelsensitive lung cancer cells undergoing apoptosis in response to Paclitaxel.
We next performed an unbiased screen of potential proteins that are secreted from A549
cells and may induce apoptosis in Paclitaxel-resistant lung cancer cells. A549 cells were
treated with Paclitaxel and the CM was applied to the A549TR cells. The CM was incubated
with antibodies against potential candidate proteins that are known to be secreted and induce
apoptosis. Rather surprisingly, although the A549 or A549TR cells are resistant to Par-4, the
Par-4 antibody caused ~70% decrease in apoptosis by the CM, relative to the control IgG
(Figure S1B). By contrast, the maspin antibody caused ~30% decrease in apoptosis by the
CM and antibodies for TRAIL, IGFBP3, GDF15 did not inhibit apoptosis by the CM
(Figure S1B). These findings implicated a Par-4-like factor in paracrine apoptosis of
Paclitaxel-resistant A549TR cells.

Author Manuscript

A Par-4-like candidate factor is involved in paracrine apoptosis of diverse therapy-resistant
cancer cells
To identify the Par-4-like factor that produced apoptosis in therapy-resistant cells, we treated
A549 lung cancer cells with Paclitaxel and applied the CM to A549TR cells in the presence
of a control IgG antibody, Par-4 N-terminal antibody, or Par-4 C-terminal antibody.
Interestingly, apoptosis by the CM was neutralized by the N-terminal antibody but not by the

Cancer Res. Author manuscript; available in PMC 2018 August 01.

Hebbar et al.

Page 6

Author Manuscript

C-terminal antibody or the control antibody (Figure 2A, lower left panel). Although residual
PCT is expected to be carried over in the CM, A549TR cells are resistant to PCT (Figure
2A, lower right panel). Apoptosis of A549TR cells treated with the CM from A549 cells is
caused by Par-4, as the apoptotic activity of the CM is neutralized by the Par-4 antibody
(Figure 2A, lower left panel). Western blot analysis of the CM from lung cancer cells that
were treated with Paclitaxel (Figures 2A and S2B), TRAIL or doxorubicin (Figure S2A),
which induce apoptosis, resolved 3 distinct bands: (1) full-length Par-4 at ~40 kDa detected
by both the N- and C-terminal Par-4 antibodies, (2) a 25 kDa band detected by the Cterminal antibody, and (3) a 15 kDa band detected by the N-terminal antibody. Because the
N-terminal antibody, which neutralized the apoptotic action of the CM, detected full length
Par-4 and the 15 kDa band, and because A549 cells or A549TR cells were resistant to the
action of full-length Par-4 (12,22), the 15 kDa band was a prime candidate for the paracrine
apoptotic effect of Paclitaxel in A549TR cells.

Author Manuscript
Author Manuscript

We further validated the concept using diverse therapy-resistant cell culture models. TRAILsensitive PC-3 cells were treated with TRAIL, and the CM was applied to TRAIL-resistant
DU145 cells (Figures 2B and S2B). Similarly, LNCaP cells, which are sensitive to
bicalutamide, were treated with bicalutamide and the CM was applied to bicalutamideresistant DU145 cells (Figures 2C and S2B). We also treated MEL cells Mel1617, which are
sensitive to the mutant BRAF inhibitor PLX4720, and the CM was applied to Mel1617BR
melanoma cells, which are resistant to PLX4720 (Figures 2D and S2B). Interestingly, the
CM from the TRAIL, bicalutamide, or PLX4720-treated therapy-sensitive cancer cells
produced apoptosis in the corresponding therapy-resistant cells (Figures 2 B–D).
Importantly, the apoptotic activity in the CM from the TRAIL-treated or bicalutamidetreated therapy-sensitive cancer cells was neutralized by the N-terminal Par-4 antibody but
not the C-terminal Par-4 antibody, and the 15 kDa band detected by the Par-4 N-terminal
antibody was present in the CM (Figures 2B, 2C and S2B). The 15 kDa band was also
present in the CM from the PLX4720 treated therapy-sensitive cancer cells, and the
apoptotic activity of the CM was neutralized by the N-terminal Par-4 antibody, as well as by
the C-terminal Par-4 antibody (Figures 2D and S2B). These findings suggested that the 15
kDa band represented a candidate factor released by therapy-sensitive cancer cells that may
effectively induce apoptosis in therapy-resistant cancer cells.
Identification of PAF

Author Manuscript

Since TRAIL, Paclitaxel, bicalutamide or PLX4720 induced apoptosis through the activation
of intracellular caspases (20,23–25), we considered the possibility that the 15 kDa and 25
kDa bands represented N- and C-terminal caspase-cleavage fragments, respectively, of
Par-4. An in silico search of caspase cleavage sites within Par-4 identified a potential
cleavage site at the D131 position (D131EEEPD). During the course of these studies, several
groups identified D131 as a target for caspase-3 and focused on the role of the 25 kDa
fragment, which contains the SAC effector domain of Par-4, but did not specifically identify
the 15 kDa fragment (26–28). Pretreatment of H460 cells with TRAIL in the presence of
cycloheximide, which is known to inhibit de novo protein biosynthesis, did not inhibit
production of the 25 kDa and 15 kDa bands (Figure S3A), indicating that production of
these fragments was not dependent on new gene expression events. We also transfected
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H460 cells with Par-4 that was tagged with GFP at the C-terminus (Par-4 CT-GFP), which is
known to activate caspase-dependent apoptosis (29). Despite fusion of GFP at the Cterminus, Par-4-CT-GFP produced the 15 kDa band, indicating that the 15 kDa fragment was
not a result of alternate splicing or antibody cross-reaction with other proteins (Figure S3B).
On the other hand, pretreatment of cells with the pan-caspase inhibitor zVAD-fmk inhibited
the generation of the 25 kDa and 15 kDa fragments, confirming that these fragments were
produced by caspase-dependent cleavage of Par-4 (Figure 3A). As expected, ectopic
expression of full length Par-4, which produces apoptosis in H460 cells, produced the 25
kDa and 15 kDa fragments, and the products of the 1-131aa or 132-340aa deletion mutant
constructs of Par-4 co-migrated with the 15 kDa or 25 kDa band, respectively (Figure 3A).
By contrast, overexpression of Par-4 D131A mutant, which is expected to be resistant to
caspase activity, failed to produce the Par-4 cleavage fragments (Figure 3A). Moreover,
TRAIL, which activated caspase-3 (25,30), further induced the production of the 25 kDa and
15 kDa bands in TRAIL-sensitive cells transfected with the Par-4 expression construct but
not with the D131A mutant of Par-4, relative to vector (Figure S4). Together, these findings
indicated that the 15 kDa band was produced by caspase cleavage of Par-4, and that the
D131 residue was critical for caspase induced cleavage of Par-4. We designated this
1-131aa/15 kDa, fragment as PAF (Par-4 Amino-terminal Fragment).
PAF induces apoptosis selectively in cancer cells

Author Manuscript

To interrogate whether PAF was sufficient to induce apoptosis, we transfected 3T3
fibroblasts with vector, human Par-4 or PAF expression constructs, and the CM from the
cells was transferred to diverse normal or cancer cell lines. The CM from PAF transfected
cells induced apoptosis in diverse cancer types, regardless of whether they were sensitive or
resistant to apoptosis by the CM from Par-4 transfected cells, but not in normal cells (Figure
S5). To further confirm our findings on the cancer-specific apoptotic potential of PAF, we
used recombinant PAF. As seen in Figure 3B, recombinant PAF induced apoptosis in Par-4resistant cancer cells, as well as Par-4-sensitive cancer cells, but not in normal cells.
Together, these findings indicate that PAF induces apoptosis specifically in cancer cells,
including those that are resistant to apoptosis by exogenous full length Par-4.
Mechanism of PAF induced apoptosis

Author Manuscript

As Par-4 induces apoptosis via the caspase 8/caspase 3-dependent pathway (15), we sought
to determine whether PAF utilized a similar or distinct apoptotic mechanism. We transfected
MEFs with vector, Par-4 or PAF expression constructs, and the CM was applied to A549
cells in combination with various caspase inhibitors. Apoptosis by PAF was blocked by the
pan-caspase inhibitor (zVAD-fmk), caspase 8 inhibitor (zIETD-fmk), and caspase 3 inhibitor
(zDEVD-fmk), and relatively weakly by the caspase 9 inhibitor (zLEHD-fmk) (Figure S6).
The caspase 8/caspase 3 pathway requires functional FADD for activation of caspase 8
activation, which then directly activates effector caspase 3 or the mitochondrial/caspase 9
pathway through cleavage of t-BID (31–33). To confirm the requirement of the caspase 8/
caspase 3 pathway in the action of PAF, we treated PC-3 parent cells or PC-3 transfectants
expressing dominant negative (dn) FADD (to block FADD activation) or FLIP (to inhibit
caspase 8 activation) with recombinant PAF, Par-4, or TRX control protein. PAF induced
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apoptosis in PC-3 cells with an intact extrinsic apoptotic pathway but not in PC-3 cells
expressing dnFADD or FLIP (Figure 3C). These findings indicated that FADD/caspase 8/
caspase 3 pathway was essential for apoptosis by PAF.

Author Manuscript

Extracellular Par-4 is known to induce apoptosis by binding to GRP78 at the cell surface
(15). PAF is able to induce apoptosis in Par-4 resistant cell types such as A549 or DU145,
which display low levels of cell surface GRP78 (15), suggesting that the action of PAF may
be independent of GRP78. To directly verify the cell surface GRP78-independent action of
PAF, we transfected Par-4-null MEFs with vector, Par-4 and PAF and the CM was applied to
A549TR and H460 cells in the presence of antibodies to Par-4 and GRP78. The Par-4
antibody inhibited apoptosis by both PAF and Par-4 (Figure 3D). The antibody to GRP78
was unable to inhibit apoptosis in PAF treated cells but apoptosis in Par-4 treated cells was
significantly reduced (Figure 3D), thereby confirming that PAF induced apoptosis
independent of cell surface GRP78.
The VASA domain within PAF is essential for apoptosis by Par-4 or PAF
To identify the domains of PAF that are critical for apoptosis of cancer cells, we generated
deletion mutants of PAF. MEFs were transfected with these mutants and the CM was tested
for apoptosis in A549 and PC-3 cells. These experiments indicated that the most active
region of PAF was localized between amino acids 60 and 90 (Figure S7 A–C).

Author Manuscript

A screen for molecular signatures of potentially functional domains within the 60-90aa
residues of PAF revealed a VASA segment (ELNNNL) that is important for Par-4-binding to
the SPRY domain of the E3 ubiquitin ligases, Fbxo45, SPSB1, SPSB2, and SPSB4 (19,34).
Our recent studies indicated that Fbxo45 causes rapid degradation of Par-4 by binding to the
VASA segment (19). We therefore examined whether the VASA segment within PAF was
essential for apoptosis of cancer cells. H460 cells were transfected with expression
constructs for Par-4, Par-4 with an ALANAL mutation introduced within its VASA segment
(Par-4/3A), and vector for control. Western blot analysis of the CM from the H460
transfectants indicated cleavage of both wild type Par-4 and Par-4/3A mutant to generate the
15 kDa PAF fragment or PAF-mutant fragment, respectively (Figure 4A). The CM from
Par-4 transfectants but not from Par-4/3A mutant transfectants induced apoptosis in the
Par-4- and/or therapy-resistant A549 and A549TR cells (Figure 4A). As expected, Par-4sensitive PC-3 and Mel1617BR cells were sensitive to both Par-4 and Par-4/3A mutant in the
CM (Figure 4A).

Author Manuscript

We also generated a PAF/3A-mutant containing an ELNNNL to ALANAL mutation and
transfected Par-4-null MEF cells with this mutant or with PAF expression construct or vector
for control. The CM from PAF transfectants but not from PAF/3A mutant transfectants
induced apoptosis in A549TR cells (Figure 4B). To determine whether the VASA segment
was sufficient to induce apoptosis in therapy-sensitive and therapy-resistant cells, we used a
16aa synthetic peptide containing Par-4 residues 68 to 73 or a 16aa VASA mutant containing
the ALANAL sequence. The 16aa peptide but not the mutant peptide induced apoptosis in
both therapy-sensitive and therapy-resistant cancer cells (Figure 4C). Collectively, these
findings indicate that the pro-apoptotic activity of PAF was dependent on its VASA segment.

Cancer Res. Author manuscript; available in PMC 2018 August 01.

Hebbar et al.

Page 9

Author Manuscript

Finally, to test the efficacy of PAF in tumor growth inhibition, immunocompromised mice
were injected intravenously with LLC-1 cells followed by injection of the His-PAF or HisTRX control protein. His-PAF induced significant inhibition of lung tumor growth compared
to control protein (Figure 4D). These results indicate that PAF is sufficient to cause tumor
growth inhibition in vivo.
Extracellular PAF selectively enters cancer cells and competes with Par-4 binding to
Fbxo45

Author Manuscript

To determine whether intracellular Par-4 function was essential for apoptosis by PAF, Par-4null MEFs were transfected with PAF or PAF-ALANA mutant, Par-4, or vector for control.
The CM from the transfectants was applied to the A549 cells with either shRNA knockdown
levels of Par-4 or control shRNA. Cells with basal levels of Par-4 but not knockdown levels
of Par-4 showed apoptosis in response to PAF; and mutant PAF failed to induce apoptosis
(Figure 5A). These findings indicate that intracellular Par-4 is essential for apoptosis by
extracellular PAF.
We then examined whether extracellular PAF can translocate into the cells to utilize
intracellular Par-4 function. Cells were treated with His-tagged PAF and intracellular
presence of the His-tagged peptide was examined by ICC and confocal microscopy. His-PAF
was detected in the cytoplasm in A549TR and H460 cells but not in Beas-2B and MEF cells
(Figure 5B and Figure S8). By contrast, heat-inactivated His-PAF control peptide failed to
translocate into the cells. These observations indicate that extracellular PAF selectively
enters the cancer cells to execute its effect intracellularly.
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As intracellular Par-4 is ubiquitinated and degraded following binding to Fbxo45 (19), we
examined whether extracellular PAF stabilizes intracellular Par-4. Par-4-null MEFs were
transfected with PAF or vector for control, and the CM was transferred to A549TR or H460
cells for 5 h in the presence of cycloheximide, which prevents de novo protein synthesis.
Treatment with CM containing extracellular PAF but not CM containing PAF/3A caused
stabilization of intracellular Par-4 levels (Figure 5C).
As intracellular Par-4 is degraded by ubiquitin ligase Fbxo45, yet PAF stabilizes intracellular
Par-4, we examined whether PAF competes with binding of Par-4 to Fbxo45. A549TR cells
were treated with His-PAF or heat-inactivated His-PAF and the lysates were subjected to coimmunoprecipitation with Fbxo45 antibody. As seen in Figure 5D, extracellular His-PAF,
but not heat-inactivated His-PAF, reduced binding of Par-4 to Fbxo45. Collectively these
results indicate that application of PAF extracellularly facilitates the stabilization of Par-4 by
preventing degradation of Par-4.
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Discussion
Heterogeneity of tumors poses a significant challenge to cancer therapy due to the existence
of drug resistant cell populations. Our present study indicates that treatment of therapysensitive cancer cells with chemotherapeutic agents leads to apoptosis of therapy-resistant
cancer cells in culture. Importantly, growth of therapy-resistant tumor cells was also
inhibited by therapy that was administered to xenografts containing a heterogeneous
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population of both therapy-sensitive and therapy-resistant tumor cells. By contrast,
xenografts containing only therapy-resistant tumors were not inhibited by the same
therapeutic regimen. These observations supported the release of a factor(s) from dying
therapy-sensitive tumor cells to induce apoptosis in therapy-resistant tumor cells, leading to
tumor growth inhibition. Although previous studies indicate that dying cells release tumor
cell-inhibitory factors, the precise factor(s) released during the process has been elusive (16).
We identified this factor as PAF, a previously unidentified 15 kDa caspase-cleavage
fragment of the tumor suppressor Par-4. PAF is produced by cleavage of Par-4 at the D131
residue and is preferentially shed into the tumor cell microenvironment for paracrine
apoptosis of both therapy-sensitive and therapy-resistant tumor cells, including those that are
resistant to secreted Par-4. We noted that PAF protein inhibits the growth of tumors in mice.
Most importantly, we identified the VASA domain of Par-4 that resides within PAF, as an
essential domain for the apoptotic action of PAF. Intracellular Par-4 is typically sequestered
and degraded by the ubiquitin ligase Fbxo45 (19). Our studies indicated that PAF
translocates selectively into cancer cells and serves as a decoy by binding, via its VASA
segment, to Fbxo45, and thereby releases intracellular Par-4 for apoptosis of cancer cells.
Thus, cancer therapeutics that target sensitive populations of tumor cells exhibit a built-in
mechanism for targeting therapy-resistant cells via cleavage of Par-4 and release of PAF.
However, as tumor cells ultimately develop resistance to therapy, our ongoing studies are
directed toward understanding the parameters that may contribute to resistance to PAFmediated apoptosis, in an effort to harness PAF to overcome resistance to therapy.
PAF extends the target range of Par-4 to therapy-resistant cancer cells
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Tumor heterogeneity is a roadblock in the treatment of cancer. However, as sensitive cells
within the population are expected to release diverse factors when treated with cancer
therapeutics, we hypothesized that such factors may perturb the resistant population. Rather
unexpectedly, we identified PAF, a fragment of Par-4 shed by therapy-sensitive cancer cells
undergoing apoptosis that can kill both therapy-sensitive and therapy-resistant cancer cells.
The target range of PAF is not limited to any single type of cancer. We noted that lung
cancer cells resistant to taxanes, prostate cancer cells resistant to TRAIL or bicalutamide,
and melanoma cells resistant to the mutant-BRAF-inhibitor PLX4720 were sensitive to
apoptosis by PAF. Interestingly, when Par-4 is intact, it does not induce cell death in most of
the therapy-resistant lung or prostate cancer cells. In fact, the VASA domain within the PAF
residues in intact Par-4 compromises the stability of Par-4 by serving as a binding motif for
ubiquitin ligases such as Fbxo45 that degrade Par-4 (19). Our studies indicate that when
Par-4 is naturally cleaved by caspase action to produce PAF, or when PAF is provided
exogenously to cancer cells, it can enter cancer cells then bind to Fbxo45 and stabilize
intracellular Par-4. The finding that PAF induces apoptosis, as judged by caspase 3 ICC and
DAPI positivity, was corroborated in an independent automated assay for cell death (Figure
S9 A–D). We further showed that PAF competes with the binding of ubiquitin ligase Fbxo45
to Par-4, thereby allowing Par-4 to stay physically and functionally intact and induce
apoptosis of the cancer cells, regardless of whether they are sensitive or resistant to therapy.
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The VASA domain of PAF interacts with ubiquitin ligase complexes
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Our present studies indicated that the VASA domain located within PAF is important for
competitive binding of PAF to Fbxo45, in order to release Par-4 for apoptosis. Fbxo45 binds,
via its SPRY module, to the VASA domain of Par-4 (19). The SPRY domain of several other
proteins, such as the SSB family proteins (SSB-1, -2, and -4), binds to the VASA module of
Par-4 (34). Like many SOCS box-containing proteins, the SSB family proteins could
function as receptors for substrate proteins that are ubiquitinated by cullin-based ubiquitin
ligases (35, 36); however, their precise role in Par-4 regulation in cancer cells has not been
fully delineated. The findings of the present study raise the possibility that the PAF domain,
acting as a decoy via its VASA sequence, may modulate the interaction of other members of
the family of SPRY domain containing proteins with their substrates.
PAF induces apoptosis selectively in cancer cells

Author Manuscript

It is particularly noteworthy that PAF induces apoptosis exclusively in cancer cells but not in
normal cells. This finding is consistent with the finding that PAF selectively enters cancer
cells, not normal cells. Accordingly, in the presence of PAF, binding of ubiquitin ligases to
intracellular Par-4 is blocked in cancer cells, so that Par-4 induces apoptosis via activation of
FADD/caspase 8/caspase 3. As cellular entry is essential for apoptosis of the cancer cells,
the precise mechanism conferring selective cellular entry to PAF in cancer verses normal
cells is currently under investigation in the laboratory.
PAF action in therapy-resistant tumors

Author Manuscript

Our study suggests that cancer-therapeutics that can induce a pro-apoptotic response in
therapy-sensitive cancer cells may alter the tumor microenvironment, thereby making it
conducive to apoptosis of therapy-resistant tumor cells. However, we noted that only about
50–60% of the cells in culture undergo apoptosis with PAF. This finding implies that PAF is
unable to achieve its full potential. Escape from PAF-mediated apoptosis may be attributed
to several factors that constitute the complex and heterogeneous tumor microenvironment. A
recent study has indicated the emergence of therapy-resistant clones within heterogeneous
tumors owing to activation of cell survival kinases such as Akt1 (37). As Akt1 is known to
bind to Par-4 and inhibit Par-4 inducible apoptosis (10), emerging clones with elevated Akt1
activity may be resistant to PAF-induced apoptosis.
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In summary, we identified a caspase-cleavage fragment of Par-4, designated as PAF, which
is naturally produced and shed into the microenvironment by diverse cancer cells undergoing
apoptosis in response to chemotherapeutic agents. PAF kills both therapy-sensitive and
therapy-resistant cancer cells, causing growth inhibition of heterogeneous tumors containing
therapy-resistant tumor cells. The action of PAF was attributed to its ability to translocate
selectively into cancer cells and bind, via its VASA segment, to ubiquitin ligases such as
Fbxo45 that contain the SPRY domain. Thus, PAF acts as a molecular decoy to rescue Par-4
from ubiquitin ligase-dependent degradation, so that Par-4 can induce apoptosis of cancer
cells. As PAF selectively induces apoptosis in cancer cells but not in normal cells, this
function of PAF can be harnessed to overcome therapeutic resistance in tumors.
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Figure 1. Paclitaxel treatment of heterogeneous cultures induces apoptosis in both sensitive and
resistant cells

(A) Paclitaxel induces apoptosis in Paclitaxel-resistant cells A549TR/GFP co-cultured
with Paclitaxel-sensitive cells A549/RFP. Cells were grown separately (as individual
cultures, upper middle and right panels) or co-cultured as a 1:1 mixture (1 × 106 each)
(upper left panel), and treated with Paclitaxel (PCT, 25 nM) or vehicle for 24 h. The cells
were then stained with DAPI to reveal their nuclei (upper panels). Apoptotic cells were
quantified (lower panels) as indicated in Supplemental Materials and Methods section. Three
independent experiments were carried out, and the results in the graphs represent mean ± SD
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from three independent experiments. Asterisk (*) indicates statistical significance (P <
0.001) based on Student’s t test. A549/RFP cells (thick arrows) and A549TR/GFP cells (thin
arrows) underwent apoptosis when treated with Paclitaxel in co-cultures.
(B) Paclitaxel induces apoptosis in Paclitaxel-resistant cells within tumors containing
Paclitaxel-sensitive cells. A549 cells or A549TR/GFP cells were injected separately (upper
middle and upper right panels) or co-injected as a 1:1 mixture (1.5 × 106 cells of each)
(upper left panel) into the flanks of nude mice. When the tumors had grown to a volume of
approximately 50 mm3 (Day 0, black arrow), the mice were injected i.p. with Paclitaxel
(PCT) or vehicle. Six mice were used for each treatment group and tumor volumes for each
mouse over a 24-day period are shown. Asterisk (*) indicates that the mixed tumors treated
with PCT were significantly smaller in volume (P < 0.025 by Student’s t test) compared to
A549TR/GFP tumors treated with PCT.
Sections of the mixed tumors or A549TR-tumors were scored for GFP expression or
apoptosis by TUNEL assays (lower left panels). Data show percentage of GFP-positive cells
that were also TUNEL-positive in three different tumors, and mean ± SD values are
presented. Arrowheads indicate representative GFP-positive cells that are also TUNELpositive. Asterisks (**) indicate statistical significance (P < 0.001) based on Student’s t test.
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Figure 2. The 15 kDa amino-terminal fragment of Par-4 is involved in paracrine apoptosis of
therapy-resistant cancer cells

(A) Paracrine apoptosis of Paclitaxel-resistant A549TR cells. A549 cells were treated for
24 h with vehicle (V) or Paclitaxel (PCT, 25 nM). The CM from the vehicle- or PCT-treated
cells was then pre-incubated with Par-4 N-terminal (NT) or C-terminal (CT) antibody (Ab)
or control IgG, and then applied to the PCT-resistant A549TR cells for 24 h (middle panel).
As controls, the A549 or A549TR cells were directly treated with vehicle (V) or PCT for 24
h (right panel).
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(B) Paracrine apoptosis of TRAIL-resistant DU145 cells. PC-3 cells were treated for 24 h
with vehicle (V) or TRAIL (100 ng/ml). The CM from the vehicle- or TRAIL-treated cells
was pre-incubated with Par-4 (NT) or (CT) antibody or control IgG, and then applied to the
TRAIL-resistant DU145 cells for 24 h (middle panel). As controls, PC-3 and DU145 cells
were directly treated with vehicle (V) or TRAIL (100 ng/ml) for 24 h (right panel).
(C) Paracrine apoptosis of bicalutamide-resistant DU145 cells. LNCaP cells were treated
for 24 h with vehicle (V) or bicalutamide (BIC, 70 μM). The CM from the vehicle- or BICtreated cells was pre-incubated with Par-4 (NT) or (CT) antibody or control IgG, and then
applied to the BIC-resistant DU145 cells for 24 h (middle panel). As controls, LNCaP and
DU145 cells were directly treated with vehicle (V) or BIC (70 μg/ml) for 24 h (right panel).
(D) Paracrine apoptosis of PLX4720-resistant Mel1617BR cells. Mel1617 cells were
treated for 24 h with vehicle (V) or PLX4720 (PLX, 2.5 μM). The CM from the vehicle- or
PLX4720-treated Mel1617 cells was pre-incubated with Par-4 (NT) or (CT) antibody or
control IgG, and then applied to the PLX472–resistant Mel1617BR cells for 24 h (middle
panel). As controls, Mel1617 and Mel1617BR cells were directly treated with vehicle (V) or
PLX4720 (2.5 μM) (right panel).
(A–D) Western blot analysis was performed on the whole-cell lysates and CM with the
indicated antibodies (left panels). Uncut gels are shown in Supplementary Figure S2 A–D.
The cells were scored for apoptosis by ICC for active caspase 3 (middle and right panels).
Three independent experiments were carried out, and the apoptosis data represent mean ±
SD from three independent experiments. Asterisk (*) indicates statistical significance (P <
0.001) based on Student’s t test.
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Figure 3. Discovery and validation of PAF

(A) The 25 kDa and 15 kDa fragments are produced by caspase-dependent cleavage of
Par-4 at its D131 residue. Cells were treated with vehicle or TRAIL (100 ng/ml) in the
presence or absence of zVAD-fmk (left panel), or transfected with the indicated expression
constructs or vector control (right panel). Whole cell lysates were then subjected to Western
blot analysis.
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(B) Recombinant PAF induces apoptosis specifically in cancer cells. A panel of cancer or
normal cell lines was treated with recombinant TRX, TRX-Par-4 or TRX-PAF (100 nM
each) for 24 h and scored for apoptosis.
(C) PAF induced apoptosis is dependent on FADD and caspase 8. PC-3 cells expressing
dnFADD or FLIP, or parent PC-3 cells were treated with recombinant TRX, TRX-Par-4 or
TRX-PAF (100 nM each) for 24 h and scored for apoptosis.
(D) PAF induced apoptosis is independent of cell surface GRP78. Par-4-null MEF cells
were transfected with vector, Par-4 or PAF and expression of Par-4 or PAF in the CM was
confirmed by Western blot analysis (lower panel). The CM was preincubated with antibody
(Ab) for Par-4 (NT), GRP78 or control IgG, then applied to A549TR and H460 cells for 24
h to score for apoptosis (upper panel).
(B–D) The cells were scored for apoptosis by ICC for active caspase 3. The apoptosis data
represent mean ± SD from three independent experiments. Asterisk (*) indicates statistical
significance (P < 0.001) based on Student’s t test.
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Figure 4. The VASA segment of PAF is essential for apoptosis
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(A) The VASA domain is necessary for Par-4-induced apoptosis in Par-4-resistant
cancer cells. H460 cells were transfected with expression constructs for Par-4, Par-4/
ALANAL mutant (Par-4/3A), or vector for control for 24 h. The CM from the transfectants
was confirmed for generation of the PAF fragment (left panel) and then transferred to cancer
cells for 24 h. The cells were scored for apoptosis (right panel).
(B) The VASA domain is necessary for PAF induced apoptosis. Par-4 null MEFs were
transfected with expression constructs for PAF, PAF/ALANAL (PAF/3A) mutant or vector
and expression of the constructs was confirmed by Western blot analysis (right panel). The
CM from the transfectants was then applied to A549TR cells for 24 hours to score for
apoptosis (left panel).
(C) A short peptide containing the VASA domain induces apoptosis. Cancer cells were
treated for 24 h with a 16aa synthetic peptide containing the VASA segment (ELNNNL), a
16 amino acid VASA/3A mutant (ALANA) peptide, or vehicle control. The cells were
scored for apoptosis.
(A–C) The apoptosis data represent mean ± SD from three independent experiments.
Asterisk (*) indicates statistical significance (P < 0.001) based on Student’s t test.
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(D) PAF inhibits tumor growth in vivo. Immunocompromised mice were injected with
LLC1 cells, and then with His-PAF or His-TRX protein (250 μg). Six mice were used for
each treatment group. After 18 days, the animals were sacrificed, the lungs were injected
with India ink and the tumor nodules were counted. Asterisks (**) indicates statistical
significance (P < 0.02) based on Student’s t test.
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Figure 5. Mechanism of apoptosis by PAF

(A) Intracellular Par-4 function is essential for apoptosis by extracellular PAF. Par-4
null MEFs were transfected with expression constructs for Par-4, PAF, PAF/3A mutant or
vector and expression of the constructs was confirmed by Western blot analysis (right panel).
The CM was applied to A549 cells that were stably expressing control shRNA or Par-4
shRNA. Par-4 knockdown was confirmed by Western blot analysis (middle panel). The cells
were scored for apoptosis by ICC for active caspase 3 after 24 hours of treatment (left
panel). The apoptosis data represent mean ± SD from three independent experiments.
Asterisk (*) indicates statistical significance (P < 0.001) based on Student’s t test.
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(B) Extracellular PAF selectively enters cancer cells, not normal cells. Cells were treated
with His-tagged PAF (100 nM) or heat-inactivated (HI) PAF (100 nM) as control, and the
intracellular presence of the His-tagged protein was examined by ICC and confocal
microscopy (left panels). Image magnification = 40×. PAF was analyzed by SDS-PAGE and
Coomassie blue staining (right panel).
(C) Extracellular PAF stabilizes intracellular Par-4. CM from Par-4-knock out (KO)
MEFs transfected with PAF or vector (as indicated above in Panel A), was transferred to
A549TR or H460 cells for 5 h in the presence of cycloheximide (10 μg/ml) or vehicle
control. Cell lysates were examined by Western blot analysis for stabilization of intracellular
Par-4 by PAF from the CM.
(D) Extracellular PAF binds to Fbxo45 and prevents Par-4 binding to Fbxo45. A549TR
cells were treated with purified His-PAF or heat-inactivated His-PAF (C) and the lysates
were subjected to co-immunoprecipitation with Fbxo45 antibody and Western blot analysis
for Par-4 and PAF with the Par-4 N-terminal antibody. Input lysate was used as control.
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